TheraRadar
DNLI

Filed

FDA PDUFA Target Action Date · Denali Therapeutics Inc.

Sunday, April 5, 2026
Approved March 24, 2026
approved

Drug Information

Drug Name
Filed (CT.gov)
Application Type
Priority Review
Approved As
AVLAYAH →

Filing Details

Stock Ticker
DNLI
SEC CIK
0001714899

What is a PDUFA Date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.

  • Standard Review: 10 months from filing acceptance
  • Priority Review: 6 months from filing acceptance
  • Possible Outcomes: Approval, Complete Response Letter (CRL), or extension

Explore Denali Therapeutics Inc.

View Denali Therapeutics Inc.'s full pipeline, approved drugs, and clinical trials.

Data sourced from SEC EDGAR filings. Last updated: 2025-12-04. Report an issue